Key result
Exposure to antidepressants, including SSRIs (AOR 1.01; 95% CI 0.87-1.19; P=0.962), SNRIs, and TCAs, was not associated with an increased risk of developing type 2 diabetes in patients with depression.
Why the study?
The increased risk of type 2 diabetes mellitus among antidepressant users might be mediated by depression, prompting investigation into whether antidepressants and their serotonin transporter binding affinities are associated with diabetes risk in depressed patients.
Does antidepressant exposure increase the risk of Type 2 Diabetes Mellitus in patients with depression?
Case-Control (n=3,038)
Does antidepressant exposure increase the risk of Type 2 Diabetes Mellitus in patients with depression?
Answers are grounded in this paper and cite their sources.
Antidepressant use is not associated with an increased risk of developing type 2 diabetes mellitus in patients with depression.
PURPOSE/BACKGROUND: The increased risk of type 2 diabetes mellitus (T2DM) among users of antidepressants (ADs) might be mediated by depression. We investigated whether ADs are associated with increased risk of T2DM in patients with depression. Moreover, the relationship between binding affinities of serotonin transporter (SERT) of ADs and the risk of T2DM is examined. METHODS/PROCEDURES: We conducted a retrospective nested case-control study using data from Taiwan's National Health Insurance Research Database between 2000 and 2013. A total of 3038 patients with depression, 1519 cases of T2DM, and 1519 controls matched for age, sex, and index date, were included. Exposure to ADs was categorized by type and SERT. The association between AD exposure and T2DM development was assessed using conditional logistic regression analysis. FINDINGS/RESULTS: No association between T2DM development and selective serotonin reuptake inhibitors (adjusted odds ratio [AOR], 1.01; 95% confidence interval [CI], 0.87-1.19; P = 0.962), serotonin-norepinephrine reuptake inhibitors (AOR, 1.13; 95% CI, 0.94-1.37; P = 1.196), tricyclic antidepressants (AOR, 1.01; 95% CI, 0.85-1.21; P = 0.906), or others (AOR, 0.88; 95% CI, 0.75-1.03; P = 0.104) was found. Alternatively, no association between individual ADs and potency of affinity to SERT and the risk of T2DM was found. IMPLICATIONS/CONCLUSIONS: No association between ADs and increase risk of T2DM was found in patients with depression. However, regular metabolic evaluations are recommended for patients with depression regularly taking ADs.
No takes yet. Share an insight, caveat, or question.
Kuo et al. (2020) conducted a case-control in Depression (n=3,038). Antidepressants vs. Matched controls without type 2 diabetes was evaluated on Development of type 2 diabetes mellitus (AOR 1.01, 95% CI 0.87-1.19, p=0.962). Exposure to antidepressants, including SSRIs (AOR 1.01; 95% CI 0.87-1.19; P=0.962), SNRIs, and TCAs, was not associated with an increased risk of developing type 2 diabetes in patients with depression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: